Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity.

Détails

ID Serval
serval:BIB_639F1058DB58
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity.
Périodique
Allergy
Auteur⸱e⸱s
Simon D., Cianferoni A., Spergel J.M., Aceves S., Holbreich M., Venter C., Rothenberg M.E., Terreehorst I., Muraro A., Lucendo A.J., Schoepfer A., Straumann A., Simon H.U.
ISSN
1398-9995 (Electronic)
ISSN-L
0105-4538
Statut éditorial
Publié
Date de publication
05/2016
Peer-reviewed
Oui
Volume
71
Numéro
5
Pages
611-620
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Eosinophilic esophagitis (EoE) is a chronic disease characterized clinically by symptoms of esophageal dysfunction and histologically by eosinophil-predominant inflammation. EoE is frequently associated with concomitant atopic diseases and immunoglobulin E (IgE) sensitization to food allergens in children as well as to aeroallergens and cross-reactive plant allergen components in adults. Patients with EoE respond well to elemental and empirical food elimination diets. Recent research has, however, indicated that the pathogenesis of EoE is distinct from IgE-mediated food allergy. In this review, we discuss the individual roles of epithelial barrier defects, dysregulated innate and adaptive immune responses, and of microbiota in the pathogenesis of EoE. Although food has been recognized as a trigger factor of EoE, the mechanism by which it initiates or facilitates eosinophilic inflammation appears to be largely independent of IgE and needs to be further investigated. Understanding the pathogenic role of food in EoE is a prerequisite for the development of specific diagnostic tools and targeted therapeutic procedures.

Mots-clé
Allergens/immunology, Anti-Asthmatic Agents/therapeutic use, Eosinophilic Esophagitis/diagnosis, Eosinophilic Esophagitis/drug therapy, Eosinophilic Esophagitis/etiology, Eosinophilic Esophagitis/metabolism, Epithelium/immunology, Epithelium/metabolism, Epithelium/pathology, Food/adverse effects, Food Hypersensitivity/diagnosis, Food Hypersensitivity/etiology, Food Hypersensitivity/metabolism, Humans, Hypersensitivity/immunology, Hypersensitivity/metabolism, Hypersensitivity/pathology, Immunity, Innate, Immunoglobulin E/immunology, Inflammatory Bowel Diseases/diagnosis, Inflammatory Bowel Diseases/etiology, Inflammatory Bowel Diseases/metabolism, Omalizumab/therapeutic use, Skin/immunology, Skin/metabolism, Skin/pathology, Th2 Cells/immunology, Th2 Cells/metabolism, Treatment Outcome, eosinophilic esophagitis, epithelial barrier, food allergy, immune response, immunoglobulin E
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/05/2016 10:19
Dernière modification de la notice
20/08/2019 15:20
Données d'usage